Evercore ISI analyst Umer Raffat reiterated an Outperform rating on Apellis Pharmaceuticals (NASDAQ: APLS).The analyst comments "Facts: 6 cases of ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE